NUTEX InvestmentsBUD:NUTEX -0.37%50 Current Ratio is 155.53 as of Dec. 2025, which is 39% below its 10-year median of 254.23. GuruFocus rates BUD:NUTEX with a GF Score™ of 50/100 and a GF Value™ of Ft13.80 (Fairly Valued). The stock has 3 warning signs investors should review. Among 997 Drug Manufacturers companies, NUTEX Investments ranks better than 99.8% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. NUTEX Investments's current ratio for the quarter that ended in Dec. 2025 was 155.53.
NUTEX Investments has a current ratio of 155.53. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for NUTEX Investments's Current Ratio or its related term are showing as below:
BUD:NUTEX'
s Current Ratio Range Over the Past 10 Years
Min: 0.15 Med: 254.23 Max: 876.72
Current: 155.53
During the past 13 years, NUTEX Investments's highest Current Ratio was 876.72. The lowest was 0.15. And the median was 254.23.
BUD:NUTEX's Current Ratio is ranked better than 99.8% of 997
companies
in the Drug Manufacturers industry
Industry Median: 2
vs BUD:NUTEX: 155.53
NUTEX Investments (BUD:NUTEX) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
NUTEX Investments Current Ratio Related Terms
NUTEX Investments Current Ratio Historical Data
* Premium members only.
The historical data trend for NUTEX Investments's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BUD:NUTEX vs ZTS, UTHR, VTRS: Current Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, NUTEX Investments's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NUTEX Investments Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, NUTEX Investments's Current Ratio distribution charts can be found below:
* The bar in red indicates where NUTEX Investments's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NUTEX Investments (BUD:NUTEX) has a Current Ratio of 155.53 as of Dec. 2025. This is 39% below median its historical median of 254.23. Over the past decade, NUTEX Investments' Current Ratio has ranged from 0.15 to 876.72. According to the industry distribution chart, NUTEX Investments ranks #2 out of 997 companies in the Drug Manufacturers industry, placing it in the top 0.2%.
Is NUTEX Investments' Current Ratio too high?
NUTEX Investments' current Current Ratio of 155.53 is 39% below median its 10-year median of 254.23. Over the past 10 years, this metric has ranged from a low of 0.15 to a high of 876.72. The Drug Manufacturers industry median Current Ratio is 2.00. NUTEX Investments' value of 155.53 is 7676.5% above this industry median. Based on the distribution chart, NUTEX Investments ranks #2 out of 997 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, NUTEX Investments has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does NUTEX Investments' Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, NUTEX Investments ranks #2 out of 997 companies for Current Ratio. This places NUTEX Investments in the top 0% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.00. NUTEX Investments' value of 155.53 is 7676.5% above this benchmark. Historically, NUTEX Investments' own Current Ratio has ranged from 0.15 to 876.72 over the past decade. While the company's 10-year median is 254.23 vs. the industry median of 2.00, NUTEX Investments has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NUTEX Investments's current Current Ratio of 155.53 is 7676.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NUTEX Investments's current Current Ratio is 155.53, which is 39% below median its own 10-year median of 254.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NUTEX Investments stock overvalued right now?
Based on GuruFocus' analysis, NUTEX Investments (BUD:NUTEX) is currently considered Fairly Valued. The stock's GF Value™ is Ft13.80, compared to a current price of Ft13.40 — trading 2.9% below its estimated fair value. The current Current Ratio is 155.53, which is 39% below median its 10-year median of 254.23 and 7676.5% above the Drug Manufacturers industry median of 2.00. NUTEX Investments' overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For NUTEX Investments (BUD:NUTEX), the current Current Ratio is 155.53 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NUTEX Investments (BUD:NUTEX) Overvalued in 2026?
Based on GuruFocus' analysis, NUTEX Investments stock appears to be undervalued.
The current stock price of Ft13.40 is trading 2.9% below its estimated GF Value™ of Ft13.80.
GuruFocus considers NUTEX Investments to be Fairly Valued.
Key valuation signals for BUD:NUTEX:
Current Ratio: 155.53 (39% below median its 10-year median of 254.23)
GF Value™: Ft13.80 vs. price of Ft13.40 (2.9% below fair value)
Industry Position: 7676.5% above the Drug Manufacturers median (#2 of 997)
No single metric tells the full story. See the BUD:NUTEX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NUTEX Investments PLC operates as a drug manufacturer in Hungary. The company is engaged in production of products that focuses on health, vitality, and natural ingredients.
50GF Score
Get the complete analysis for BUD:NUTEX
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUD:NUTEX has been successfully added to your 
